Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

计划入组 30 人 · 首次发布于 2022 年 6 月 2 日

SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients

计划入组 36 人 · 首次发布于 2018 年 10 月 23 日

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

计划入组 190 人 · 首次发布于 2021 年 12 月 13 日

γδ T-PD-1 Ab Cells therapy(Changzhou No.2 People’S Hospital)

MV-anti-PD1

CT-011

Cambridge Antibody Technology

New Zealand

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

Camrelizumab Shows Promise in Initially Unresectable NSCLC

Junshi Biosciences Achieves Regulatory Milestone with First Domestic Subcutaneous Anti-PD-1 Antibody Application in China

LaNova Medicines Initiates Phase 1 Trial of LM-299, Anti-PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors